Sleep Apnea Device Sales Beat Analyst Estimates
Adults with obstructive sleep apnea see growing uptake of implantable nerve-stimulation therapy as an alternative to CPAP.
Updated on Nov. 3, 2026 in Sleep Disorders
Golden Valley, Minnesota-based Inspire Medical Systems reported a third-quarter net loss of $24.4 million, or 84 cents per share, on Monday, while its adjusted earnings of 14 cents per share and revenue of $206.7 million both topped analyst estimates. The maker of devices for treating obstructive sleep apnea also issued full-year guidance for the coming year.
Why it matters
For people living with obstructive sleep apnea, the results signal continued commercial growth for implantable therapies that are one of several treatment options available beyond continuous positive airway pressure (CPAP) machines. Revenue beating expectations suggests demand for the technology remains strong in the Minnesota-headquartered company's market.
These are company-reported quarterly financial results compared against Zacks analyst consensus averages, not clinical data on patient outcomes. The GAAP loss reflects restructuring and non-recurring costs, while adjusted figures exclude them, and the report does not detail the underlying causes beyond that.
The players
Inspire Medical Systems Inc.
A Golden Valley, Minnesota company that manufactures implantable devices for treating obstructive sleep apnea.
Zacks
An independent investment research firm whose analyst consensus averages served as the benchmark for Inspire's reported results.
The details
Inspire's products treat obstructive sleep apnea, a condition in which the upper airway repeatedly collapses during sleep, by stimulating the hypoglossal nerve that controls tongue movement to keep the airway open. The company reported its results on Monday, with earnings figures adjusted to exclude restructuring costs and other non-recurring items. Management also issued full-year guidance calling for earnings of $1.20 to $1.40 per share and revenue of $850 million to $860 million.
Timeline
Inspire Medical Systems reported third-quarter results on Monday, November 2, 2026.
Health Landscape
Hypoglossal nerve stimulation has emerged as an implantable option for patients who cannot tolerate or do not respond to CPAP, the long-standing first-line therapy for obstructive sleep apnea. Commercial growth in this device category reflects a broader shift toward more treatment choices for a condition that affects a large share of adults.
If you have been diagnosed with obstructive sleep apnea or have trouble tolerating CPAP, implantable stimulation therapy is one option worth raising with your sleep specialist or primary care doctor. Whether it fits your situation depends on your anatomy and sleep study results, so it is a conversation to have with your physician.
The takeaway
Expanding treatment options for obstructive sleep apnea, including device-based therapies, can matter for people who struggle with CPAP. If sleep apnea symptoms such as loud snoring, daytime fatigue, or witnessed breathing pauses sound familiar, consider discussing a sleep evaluation with your doctor.
Further reading
For broader context on treatment options, explore our Sleep Disorders coverage.
